A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy

Patel, Krishnan R.; Rowe, Lindsay; Schott, Erica; Cooley-Zgela, Theresa; Ning, Holly; Türkbey, Barış; Choyke, Peter; Lindenberg, Liza; Mena, Esther; Pinto, Peter A.; Zhang, Qihu; Shih, Joanna H.; Salerno, Kilian E.; Citrin, Deborah E.

doi:10.1016/j.adro.2022.101024

Cited by 2 publications

(2 citation statements)

References 47 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SBRT as salvage therapy for radiorecurrent prostate cancer has been used for more than 15 years (9, 10, 12). Early case series were usually done with a Cyberknife treatment machine whereas newer studies included cohorts treated with C-arm Linacs or MR Linacs (10, 12-17, 19, 22-33, 40-42, 57-63). Of the 14 studies included in this meta-analysis, only three included patients that were exclusively treated on a Cyberknife (40-42).…”

Section: Discussionmentioning

confidence: 99%

“…Noticeably, earlier studies on SBRT for radiorecurrent prostate cancer were often done using a Cyberknife treatment machine (9,10,(12)(13)(14)(15)(16). In the last years, however, there has been increasing evidence on prostate re-irradiation using a C-arm LINAC or a MR LINAC (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Re-irradiation to the Prostate using stereotactic body radiotherapy (SBRT) after initial definitive Radiotherapy – A systematic review and Meta-analysis of recent trials

Schröder,

Tang,

Buchali

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: There is increasing data on re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after definite radiotherapy for prostate cancer. There has been increasing evidence on prostate re-irradiation using a C-arm LINAC or a MR LINAC in the last years. We therefore conducted this systematic review and meta-analysis on prostate re-irradiation including studies published from 2020-2023 to serve as an update on existing meta-analysis. Methods: We searched the Pubmed and Embase databases in October 2023 with queries including combinations of "repeat", "radiotherapy", "prostate", "re-irradiation", "reirradiation", "re treatment", "SBRT", "retreatment". Publication date was set to be from 2020 to 2023. There was no limitation regarding language. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. After data extraction, heterogeneity testing using I2. Afterwards a random effects model with a restricted maximum likelihood estimator was used for estimating the combined effect. Funnel plot asymmetry was assessed visually and using Eggers test to estimate the presence of publication and/or small study bias. Results: 14 publications were included in the systematic review. The rates of acute ≥ grade 2 (G2) GU and GI toxicities reported in the included studies range from 0.0-30.0% and 0.0-25.0% respectively. For late ≥G2 GU and GI toxicity, those values are 4.0-51.8% and 0.0-25.0%. The pooled rate of acute GU and GI toxicity ≥G2 were 13% (95% CI: 7-18%) and 2% (95% CI: 0-4%). For late GU and GI toxicity ≥G2 the pooled rates were 25% (95% CI: 14-35%) and 5% (95% CI: 1-9%). The pooled 2-year biochemical recurrence-free survival was 72% (95% CI: 64-92%). Conclusions: SBRT in the re-irradiation of radiorecurrent prostate cancer is overall safe and effective also when applied with a C-arm Linac or an MR Linac. Further prospective data are warranted.

show abstract